After shelving its sickle cell program over safety concerns, Fulcrum is combining with Slate Medicines in a reverse merger built around a next-generation migraine drug.
Researchers paired live malaria parasites with a drug that stops them in the liver, converting infectious bites into immunizing events that produced durable protection in animals.
The company’s long-acting retina treatment failed to prove non-inferiority to standard therapy across the full trial, wiping out nearly $1 billion in market value.
The antibody drug improved muscle strength and function in adults with inflammatory muscle disease, setting up a potential label expansion for a therapy already generating billions.
By fusing therapeutic antibodies to albumin, researchers cut how much of the drug crosses the placenta — without sacrificing the long-lasting effect that makes these medicines useful.
The world’s largest biosimilar maker will commercialize up to 10 Henlius-developed copies of blockbuster biologics globally, positioning for one of the industry’s biggest-ever patent cliffs.
European regulators have validated the marketing application for a six-valent Lyme vaccine that showed more than 70% efficacy in a 9,437-person Phase 3 trial. No human Lyme vaccine is currently approved.
Whole-genome sequencing of the parasite behind the deadliest malaria uncovered new mutations linked to reduced susceptibility to frontline artemisinin-based therapy.
The radiodiagnostic lets PET scans visualize tau neurofibrillary tangles — a core hallmark of Alzheimer’s — complementing existing amyloid imaging in patients being evaluated for the disease.
Scientists found that triple-negative breast tumors recruit immune cells to release a protein that draws nerves inward, fueling growth. An existing drug blocked the process in mice.
Studying 107 adults aged 26 to 86, researchers found that aging muscles increasingly tense against each other around the ankle — a “safety-first” stiffening that saps push-off power.
The Raleigh biotech priced its Nasdaq debut at $13 a share to fund mizagliflozin, an oral drug aimed at the dangerous blood-sugar crashes some patients face after bariatric surgery.